Aurinia Pharmaceuticals (AUPH) Capital Leases (2023 - 2026)

Aurinia Pharmaceuticals (AUPH) has 4 years of Capital Leases data on file, last reported at $48.2 million in Q1 2026.

• Quarterly Capital Leases fell 15.22% year-over-year to $48.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.2 million (down 15.22% YoY) and the FY2025 annual result came in at $52.3 million, down 10.64% from the prior year.
• Capital Leases eased to $48.2 million in Q1 2026, from $52.3 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $79.4 million in Q2 2023 to a low of $48.2 million in Q1 2026.
• A 4-year average of $63.0 million and a median of $62.1 million in 2024 frame the typical range for Capital Leases.
• The widest YoY moves for Capital Leases: up 8.64% in 2024, down 22.42% in 2024.
• Tracing AUPH's Capital Leases over 4 years: stood at $75.5 million in 2023, then decreased by 22.42% to $58.6 million in 2024, then slipped by 10.64% to $52.3 million in 2025, then declined by 7.91% to $48.2 million in 2026.
• The last three Capital Leases figures came in at $48.2 million (Q1 2026), $52.3 million (Q4 2025), and $55.7 million (Q3 2025), per Business Quant data.